Home › Funds › Soleus Capital Management, L.P. › MBX
Soleus Capital Management, L.P. position in MBX
MBX BIOSCIENCES INC · Health Care
Soleus Capital Management, L.P. reported holding 258,897 shares of MBX (MBX BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$15.2M, representing 0.54% of its reported portfolio and ranking #47 among its reported holdings. Soleus Capital Management, L.P. has disclosed MBX holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Soleus Capital Management, L.P.'s MBX position evolved
Soleus Capital Management, L.P. first disclosed a stake in MBX in Q3 2025 at 275,000 shares (US$4.8M). The position peaked in Q2 2026 at 515,279 shares, worth US$28.4M. Across 5 filings, Soleus Capital Management, L.P. increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 258,897 shares valued at US$15.2M — a reduction of -256,382 shares quarter over quarter.. Notable position changes include a 56% trim in Q1 2026 (shares rose 85% over the following quarter), a 188% increase in Q2 2026 (shares rose 6% over the following quarter), a 50% trim in Q3 2026 (shares fell 9% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 275.00K | $4.81M | New |
| Q4 2025 | 408.90K | $12.90M | Add |
| Q1 2026 | 178.90K | $5.34M | Reduce |
| Q2 2026 | 515.28K | $28.44M | Add |
| Q3 2026 | 258.90K | $15.18M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MBX and 13F data
MBX (MBX BIOSCIENCES INC) is a Health Care company. 57 other funds we track also report a position in MBX — the largest reported positions include Frazier Life Sciences Management, L.P. (US$389.9M), Paradigm Biocapital Advisors LP (US$221.2M), NEA Management Company, LLC (US$211.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MBX
- Frazier Life Sciences Management, L.P. 6.65M sh · $389.94M · Q3 2026
- Paradigm Biocapital Advisors LP 3.77M sh · $221.17M · Q3 2026
- NEA Management Company, LLC 3.61M sh · $211.88M · Q3 2026
- ORBIMED ADVISORS LLC 3.07M sh · $180.25M · Q3 2026
- NVP Associates, LLC 2.14M sh · $125.23M · Q3 2026
- Aaron Wealth Advisors LLC 1.18M sh · $68.92M · Q3 2026
- Kynam Capital Management, LP 934.80K sh · $54.80M · Q3 2026
- EVENTIDE ASSET MANAGEMENT, LLC 873.49K sh · $51.20M · Q3 2026
- Parkman Healthcare Partners LLC 716.54K sh · $42.00M · Q3 2026
- TCG Crossover Management, LLC 650.00K sh · $38.10M · Q3 2026
- Deep Track Capital, LP 640.00K sh · $37.52M · Q3 2026
- BRAIDWELL LP 398.95K sh · $23.39M · Q3 2026
More on Soleus Capital Management, L.P.
FAQ
How long has Soleus Capital Management, L.P. held MBX?
Soleus Capital Management, L.P. has disclosed MBX holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
What is Soleus Capital Management, L.P.'s current position in MBX?
As of Q3 2026, Soleus Capital Management, L.P. holds 258.90K shares of MBX (MBX BIOSCIENCES INC), valued at $15.18M, representing 0.54% of its reported portfolio and ranking #47.
Has Soleus Capital Management, L.P. been buying or selling MBX?
In the latest 13F filing (Q3 2026), Soleus Capital Management, L.P. reduced its position in MBX. The position peaked in Q2 2026 at 515.28K shares.
Which other funds hold MBX?
Other major institutional holders of MBX include Frazier Life Sciences Management, L.P., Paradigm Biocapital Advisors LP, NEA Management Company, LLC, among 57 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.